This company listing is no longer active
Resumen de acción 3N9A
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en 3N9A a partir de nuestros controles de riesgos.
Competidores de Amryt Pharma plc
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$12.90 |
| 52 Week High | US$13.20 |
| 52 Week Low | US$6.20 |
| Beta | 0.75 |
| 1 Month Change | -0.77% |
| 3 Month Change | 0% |
| 1 Year Change | 89.71% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 38.80% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 3N9A | DE Pharmaceuticals | Mercado DE | |
|---|---|---|---|
| 7D | 0.8% | 2.6% | 2.5% |
| 1Y | 89.7% | -22.6% | 6.0% |
Rentabilidad vs. Industria: 3N9A exceeded the German Pharmaceuticals industry which returned -10.8% over the past year.
Rentabilidad vs. Mercado: 3N9A exceeded the German Market which returned -6.9% over the past year.
Volatilidad de los precios
| 3N9A volatility | |
|---|---|
| 3N9A Average Weekly Movement | 1.5% |
| Pharmaceuticals Industry Average Movement | 7.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: 3N9A's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: 3N9A's weekly volatility has decreased from 15% to 1% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2015 | 289 | Joe Wiley | www.amrytpharma.com |
Resumen de fundamentos de Amryt Pharma plc
| Estadísticas fundamentales de 3N9A | |
|---|---|
| Capitalización bursátil | €851.40m |
| Beneficios(TTM) | -€715.03k |
| Ingresos (TTM) | €220.50m |
3.9x
Ratio precio-ventas (PS)-1,191x
Ratio precio-beneficio (PE)¿Está 3N9A sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 3N9A | |
|---|---|
| Ingresos | US$243.62m |
| Coste de los ingresos | US$111.31m |
| Beneficio bruto | US$132.32m |
| Otros gastos | US$133.11m |
| Beneficios | -US$790.00k |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.012 |
| Margen bruto | 54.31% |
| Margen de beneficio neto | -0.32% |
| Ratio deuda/patrimonio | 64.3% |
¿Cómo se ha desempeñado 3N9A a largo plazo?
Ver rendimiento histórico y comparativa